Background: Olodaterol is a once-daily long-acting β2-agonist being investigated for the treatment of chronic obstructive pulmonary disease, with ≥ 24 hour bronchodilator activity.
The doses of olodaterol evaluated in the phase III program (5 and 10 µg QD) were based on the results of two phase II studies [7, 10] . As part of the phase III evaluation, the two replicate studies presented here were designed to evaluate the 24 hour Forced Expiratory Volume in 1 second (FEV1) profile of olodaterol (5 and 10 µg) QD (via the Respimat®) in comparison to placebo and to the QD LAMA tiotropium (via the HandiHaler®) over 6 weeks in patients with Global initiative for chronic Obstructive Lung Disease (GOLD) 2-4 COPD.
Methods

Patients
Patients with stable moderate to very severe COPD (GOLD 2-4) were included if they had a post-bronchodilator FEV1 <80% of predicted normal and a post-bronchodilator FEV1/forced vital capacity (FVC) <70%. Patients were current or ex-smokers with a smoking history of >10 pack-years. Key exclusion criteria included significant disease other than COPD (i.e. a disease that may put the patient at risk because of participation, may influence the results of the study, or cause concern regarding the patient's ability to participate in the study), a history of asthma, myocardial infarction in the previous year, unstable or life-threatening cardiac arrhythmia, or hospitalization for heart failure within the previous year. Patients with unstable doses of oral or inhaled corticosteroid (<6 weeks on a stable dose) or who used doses of oral corticosteroids greater than the equivalent of 10 mg per day or 20 mg every other day were also excluded.
Study design
Study 1222.39 (NCT01040689) and study 1222.40 (NCT01040728) were replicate, randomized, double-blind, double-dummy, four-way crossover (6-week treatment periods separated by a 21 day washout), placebo-and active-controlled trials. Following an initial screening visit (Figure 1 ), patients entered a baseline period of 2-6 weeks to ensure that their COPD was clinically stables (i.e. no exacerbations). Eligible patients then proceeded into the 4×6-week double-blind crossover period during which they received olodaterol 5 μg and 10 μg administered QD by the Respimat® inhaler, tiotropium (18 μg) QD via the HandiHaler®, or placebo (both Respimat® and HandiHaler®) in a randomized sequence (Figure 1 ). Each treatment phase was separated by a 21 day washout period.
Patients were evaluated for an additional 21 days following completion of the last of four 6-week periods of randomized treatment, or, in case of discontinuation, after the final dose of study medication. The overall duration of the study was 38-42 weeks (depending on the length of screening) for each patient. Study drug was self-administered (according to a double-dummy blinding approach) between 7:00 AM and 10:00 AM daily; patients inhaled olodaterol (or placebo) from the Respimat® inhaler first (two actuations) followed by tiotropium (or placebo) from the HandiHaler®. The trial was carried out in compliance with the principles laid down in the Declaration of Helsinki and in accordance with the International Conference on Harmonised Tripartite Guideline for Good Clinical Practice. Prior to study initiation, the protocol was approved by the local Institutional Review Board, Independent Ethics Committee, and the Competent Authority. All patients provided written, informed consent prior to the study commencing. Details of the local Institutional Review Board/Independent Ethics Committee are provided in Supplementary Information in e- Table 1 bPatients switched to study medication during treatment period.
cAll patients were provided with SABA as a rescue medication during this study. Short-acting muscarinic antagonists, LAMAs, and LABAs were not permitted during the treatment periods; however, patients were required to continue treatment with inhaled corticosteroids, oral corticosteroids (≤ 10 mg prednisone per day or ≤ 20 mg prednisone every other day [or equivalent]), or methylxanthines, if being used as maintenance therapy at study entry.
End points
The primary efficacy variable was FEV1. There were two co-primary efficacy end points: FEV1 area under the curve from 0-12 hours (AUC0-12) response (change from study baseline) and FEV1 area under the curve from 12-24 hours (AUC12-24) response after 6 weeks of treatment. These were calculated from zero time to 12 hours and from 12-24 hours, respectively, using the trapezoidal rule and divided by the corresponding duration (i.e. 12 hours) to give the results in liters.
FEV1 area under the curve from 0-24 hours (AUC0-24) was identified as a key secondary end point. Other secondary efficacy end points included FEV1 area under the curve from 0-3 hours (AUC0-3), trough FEV1, as well as the corresponding FVC end points (FVC AUC0-12, FVC AUC12-24, FVC AUC0-24, FVC AUC0-3, and trough FVC). In addition, a pre-specified analysis of pooled data from the two studies was conducted focusing on the comparison of olodaterol (5 μg, 10 μg) and tiotropium. Safety end points included adverse events (AEs) and serious AEs, vital signs, blood chemistry, and electrocardiogram (ECG).
Assessments
At the start of each treatment period, spirometry was conducted at 1 hour and at 10 minutes prior to administration of the morning dose of study medication and 30 minutes and 1, 2, and 3 hours post-dose. At the end of each 6-week treatment period, spirometry was repeated at 30 minutes prior to administration of the morning dose and for 24 hours post-dose (30 minutes, 1, 2, 3, 4, 6, 8, 10, 12, 22, and 23 hours, and 23 hours 50 minutes post-dose). At each time point, spirometric measurements were conducted in triplicate and the highest FEV1 and FVC from an acceptable maneuver was recorded.
At each visit, all AEs reported by the patient were recorded, irrespective of causality, and the severity of the AE was classified by a clinician. Blood pressure and pulse rate were measured prior to spirometry at all visits (and ≤ 3 hours post-dose at baseline at all treatment visits). Clinical laboratory testing (hematology, blood chemistry, and urinalysis) was performed at screening, after each randomized treatment period, and in case of premature withdrawal from the study. A standard 12 lead ECG was performed at screening for all patients. At each subsequent study visit, ECGs were performed pre-dose and repeated ~40 minutes post-dose.
Statistical analysis
It was estimated that with 80 completed patients, each study would be able to detect treatment differences of 0.060 L for FEV1 AUC0-12 response (standard deviation 0.160 L) with 91% power, and 0.060 L for FEV1 AUC12-24 response (standard deviation 0.140 L) with 96% power. Based on an estimated dropout rate of 20%, it was planned that 100 patients would be randomized.
Adjusted mean FEV1 AUC0-12 and FEV1 AUC12-24 responses were analyzed using a mixed model for repeated measurements. This model included treatment and period as fixed effects, patient as a random effect, and study baseline as a continuous covariate. For all continuous secondary end points, a mixed model for repeated measurements was performed as described for the primary analysis. Compound symmetry was used as the covariance structure for within-patient variation.
All efficacy analyses were performed on the full analysis set, which was defined as all randomized patients who received at least one dose of treatment and had a baseline and at least one post-baseline measurement.
No formal statistical analysis was planned for the safety comparisons; summary statistics are presented based on the pooled safety population (defined as all randomized patients who received at least one dose of treatment).
Results
Patient disposition and baseline characteristics
A total of 230 patients were randomized to treatment in the two studies (Figures 2a and 2b ): 108 in study 1222.39 and 122 in study 1222.40. Study 1222.39 was conducted at 15 centers in Belgium, Denmark, Germany, and Hungary, while study 1222.40 was conducted at 12 centers in Germany, The Netherlands, Norway, and the US. Both studies were conducted between January 2010 and January 2011.
All randomized patients received at least one dose of study drug and the majority completed all four treatment periods (84.3% in study 1222.39 and 78.7% in study 1222.40). AEs, including worsening of COPD, were the most frequent reasons cited for discontinuation.
The baseline demographic characteristics of patients in the two studies are shown in Table 1 . Baseline FEV1 was somewhat lower in study 1222.40 than study 1222.39, with a greater proportion of current smokers and higher usage of inhaled corticosteroids. However, patients in study 1222.40 experienced a slightly greater difference between pre-bronchodilator and post-bronchodilator FEV1 than patients in study 1222.39. 
Efficacy
For FEV1 at individual time points at week 6, there were statistically significant differences between olodaterol (both doses) and placebo (P<0.001) at each time point from 30 minutes pre-dose through to 23 hours 50 minutes post-dose (Figures 3a and 3b and Supplementary  Information [e-Figure 1] ). The 24 hour FEV1 time profiles for tiotropium were generally similar to olodaterol. FVC profiles were generally consistent with the FEV1 results (Supplementary Information [e-Figures 2a and 2b] ). 
Primary and key secondary end points
At week 6, statistically significant (P<0.0001) improvements in both FEV1 AUC0-12 and FEV1 AUC12-24 responses were observed for both doses of olodaterol and tiotropium compared to placebo in both studies (Tables 2 and 3 ). The responses were generally higher in study 1222.40 than study 1222.39.
In both studies, there were also statistically significant (P<0.0001) improvements in the key secondary end point FEV1 AUC0-24 response for both doses of olodaterol and tiotropium compared to placebo.
Other secondary end points
Results for the other secondary end points supported the primary end points and are presented in table 4 and Supplementary Information [eTables 2-5] , with significant (P<0.0001) improvements in FEV1 AUC0-3 and trough FEV1 responses for both doses of olodaterol and tiotropium compared to placebo at week 6. In addition, there were significant improvements in FVC AUC0-12, FVC AUC12-24, FVC AUC0-3, and trough FVC compared to placebo at week 6. 
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Treatment comparison: pre-specified pooled analysis
There were no differences between olodaterol 5 µg and tiotropium in FEV1 AUC0-12, AUC12-24, or AUC0-24 responses at week 6 (Supplementary Information [e- Table 6] ). There was a numerical difference in the FEV1 AUC12-24 response between olodaterol 10 µg and tiotropium at week 6 (P<0.05); differences in FEV1 AUC0-12 and AUC0-24 responses showed P values >0.05. Other than for FEV1 AUC12-24, there were no significant differences between olodaterol 5 and 10 µg (Supplementary Information [e- Table 6 ]).
Safety
No deaths were reported during the studies. Incidence of AEs was similar across the treatment groups (Table 5) , and the most frequent AEs were nasopharyngitis (19.4%), worsening of COPD (13.9%), dyspnea (6.5%), and cough (5.6%). Most events were mild or moderate in intensity and not considered related to treatment. There was a low incidence of AEs leading to discontinuation of study medication: 3.8% with placebo, 1.4% with olodaterol 5 µg, 3.3% with olodaterol 10 µg, and 2.8% with tiotropium. The most common reason for discontinuation was worsening of COPD, which occurred more frequently with placebo. Serious AEs were recorded for the individual trials by the investigators; there were 10 and 17 patients in the 1222.39 and 1222.40 studies, respectively. Two patients discontinued treatment with olodaterol 10 µg due to atrial fibrillation. In one case (a patient with a history of hypertension and an FEV1:FVC ratio of 32.5% on entry to the study), the investigator considered there was a reasonable probability of a relationship between the atrial fibrillation and treatment with olodaterol (as well as salbutamol); following discontinuation of study treatment and initiation of digitalis, the atrial fibrillation resolved. Cardiac disorders by treatment, primary system organ class, and preferred term are described in the Supplementary Information in e- Table 7 and overall blood potassium changes are included in e- Table 8 .
No changes indicative of an AE were seen for any laboratory parameters, vital signs, or ECG in either study. Table 5 : AEs occurring with an overall incidence of ≥3%a (pooled data).
aCalculated as the sum of the patients reporting AEs across all treatments in both trials divided by 230 (i.e. the safety population).
AE: Adverse Event; COPD: Chronic Obstructive Pulmonary Disease.
Discussion
These replicate studies in patients with moderate to very severe COPD demonstrated that QD olodaterol 5 and 10 µg resulted in significant improvements in FEV1 over the entire 24 hour dosing period, as demonstrated by the FEV1 AUC0-12, FEV1 AUC12-24, and FEV1 AUC0-24 responses after 6 weeks.
The tiotropium-olodaterol comparison is of particular value, as it allows the responses observed with olodaterol to be viewed in the context of those with the well-established "gold standard" treatment in COPD with a QD profile.
Similar results were observed for olodaterol 5 and 10 µg and tiotropium; while the FEV1 AUC12-24 response for olodaterol 10 μg was numerically higher than for tiotropium (P<0.05), no account was taken of multiple testing and, therefore, limited conclusions can be drawn regarding their comparative or differential efficacy. The results for the secondary efficacy end points support those of the primary end points. Indeed, the inclusion of both peak (FEV1 AUC0-3) and trough FEV1 end points (i.e. at both ends of the daily dosing profile) provide further evidence to confirm the 24 hour activity of olodaterol. These end points are of interest as they allow comparison with results from the pivotal studies within the olodaterol phase III clinical program, which were conducted under different trial conditions. In two sets of replicate studies, the mean FEV1 AUC0-3 responses (difference from placebo) ranged from 0.129-0.172 L with olodaterol 5 µg and 0.143-176 L with olodaterol 10 µg QD (ranges for trough FEV1 were 0.047-0.091 L and 0.048-0.101 L, respectively) [11, 12] . These responses are lower than in the present studies, reflecting the fact that patients in the previous studies were allowed to continue on background COPD therapies, including tiotropium. This highlights the importance of assessing the characteristics of the patient populations and background therapies when interpreting effect sizes [13] .
Differences in the magnitude of the responses observed in the two studies, with larger effects generally seen in study 1222.40, may be a reflection of different baseline characteristics in the study populations. While pre-bronchodilator FEV1 was higher in study 1222.39, FEV1 responsiveness was greater in study 1222.40; this difference in the responsiveness of the study populations is reflected in the higher FEV1 AUC0-3 responses observed in study 1222.40. Since the studies were designed and managed as replicate studies, the differences in baseline characteristics are likely due to random sampling effects.
Similar lung function responses were observed in two independent, replicate, 6-week studies of olodaterol 5 and 10 µg in comparison with twice-daily formoterol [14] . FEV1 AUC0-12 and FEV1 AUC0-24 were also used as primary end points in these trials and, taken together, the two sets of replicate studies provide a valid and rigorous means of characterizing the pharmacologic activity of olodaterol, based on 24 hour spirometry.
Further support is available from earlier phase II studies using the same primary end points, demonstrating that olodaterol 5 and 10 μg administered QD provide significant and identical bronchodilation over the complete 24 hour dosing period [5, 7] .
The data from these trials add to the comprehensive set of evidence for the efficacy and safety of QD olodaterol in COPD derived from the wider phase III olodaterol clinical program [11, 12, 14] ; this includes the 12 hour lung function testing performed in a subset of patients at 12 weeks in two replicate 48-week studies [11] .
In general, the frequency of AEs was similar with olodaterol to placebo and tiotropium, although in study 1222.40 slightly more events were observed with the 10 µg dose. The incidence of AEs typically associated with LABAs was low; while two patients were discontinued from olodaterol 10 µg due to atrial fibrillation, only in one case did the investigator consider that there was a reasonable probability of it being related to study medication.
While the studies were designed to characterize the bronchodilatory profile of olodaterol over the full 24 hour period, one limitation was the gap in the 24 hour spirometry between 12 and 22 hours post-dose, which corresponds to the time when patients were allowed to sleep in the clinic (or in a hotel close to the clinic). While this is usual practice for such studies, it might be argued that interim measurements could have been performed. However, the validity of such interim measurements is unclear, since patients would be required to conduct effort-dependent spirometric maneuvers immediately after waking during the middle of the night. Furthermore, the interrupted sleep might have impacted on the quality of the spirometry performed the following morning. As shown in Figure 3 , FEV1 time profiles over the 24 hour post-dose period were still achievable even with this necessary 8 hour interruption and indicate that olodaterol provides bronchodilation throughout the 24 hour observation period without abolishing the circadian variation.
Conclusions
These data confirm the 24 hour lung-function efficacy profile of olodaterol 5 and 10 µg QD, with FEV1 responses over 24 hours that were comparable to tiotropium. FEV1 responses were comparable between olodaterol 5 and 10 µg QD and support the selection of the 5 µg dose for later use in clinical practice. These results add to the wider evidence from the olodaterol clinical program supporting its clinical profile as an effective QD bronchodilator.
